Entelexo Analysis: $125K Raised
What is Entelexo?
Entelexo develops a proprietary platform for engineered exosome therapeutics. The company targets autoimmune diseases and states that its exosomes can deliver messages to multiple specific cell types simultaneously. Its homepage ties the platform to rheumatoid arthritis, Crohn’s disease, and psoriasis, while showing preclinical progress, patent activity, and YC participation.
Location
5270 California Ave Ste 300, Irvine, California 92617, United States
Employees
1-10
Founded
2020
Revenue
$5M
Investors
- Founders, Inc.
- Y Combinator
Product Features & Capabilities
- engineered exosomes for autoimmune diseases, therapeutic exosome-based products, rapid prototyping of therapeutics, indication-specific exosome treatments, communication with multiple cell types
How much Entelexo raised
Seed - $125,000
March 24, 2021Lead Investor: Y Combinator
Who are the founders of Entelexo
Competitors Overview
Entelexo operates in the exosome-based therapeutics market, focusing on treatments for autoimmune diseases. Its main competitors include:
-
Glycominds: This company specializes in glycoengineering and exosome-based therapies, particularly for autoimmune and inflammatory diseases. Glycominds leverages a unique approach to modify exosomes for enhanced therapeutic efficacy.
-
Chrolich Biotech: Known for its innovative biotechnological solutions, Chrolich Biotech develops exosome therapies that target various diseases, including autoimmune conditions. Their advantage lies in their proprietary technology that enhances exosome delivery and targeting.
-
Rezq Bio: This company focuses on developing exosome-based treatments for cancer and autoimmune diseases. Rezq Bio's notable advantage is its emphasis on personalized medicine, tailoring therapies to individual patient profiles.
-
Vera Therapeutics: Vera Therapeutics is engaged in developing therapies for autoimmune diseases, utilizing a combination of exosome technology and other biopharmaceutical approaches. Their strength is in their robust clinical trial pipeline and partnerships with leading research institutions.
-
Biogen: A major player in the biotechnology sector, Biogen has a diverse portfolio that includes therapies for neurological and autoimmune diseases. Their extensive resources and established market presence provide them with a competitive edge.
-
UCB: UCB is a global biopharmaceutical company that focuses on immunology and neurology. Their experience in autoimmune diseases and strong research capabilities position them as a formidable competitor.
-
Kymeratx: This company is involved in developing exosome-based therapies, particularly for chronic diseases. Their advantage is their innovative approach to exosome engineering, which aims to improve therapeutic outcomes.
Entelexo differentiates itself through its proprietary engineering platform that allows for the creation of targeted treatments, addressing the complexities of autoimmune diseases more effectively than some competitors.
Market Focus
Entelexo primarily focuses on the biotechnology industry, specifically in the development of exosome-based therapeutics for treating autoimmune diseases.
See something that needs updating? Suggest edits to this profile.